Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc. [Read more…]
Key Events in the Evolution of iPSC Products that You Need to Know
Developing induced pluripotent stem cell (iPSC) products requires a thorough understanding of the evolution of iPSC research advances. Because the cell type was recently discovered in 2006, the following presents a decade-long timeline of key events in the discovery and evolution of induced pluripotent stem cell products.
The research events below drove forward interest in the use of iPSCs for basic research and clinical applications. These events are the reason that the first clinical trial involving the implantation of iPSCs into humans was initiated in 2013, to assess the capacity of the cell type to treat loss of eyesight due to macular degeneration.
For this reason, stem cell company executives and stem cell industry investors will be better suited to make future decisions about iPSC products if they have a historical understanding of the recent past and the rate at which research advances with the cell type accelerated. [Read more…]
Do You Know The 5 Types of Dental Stem Cells?
Dental stem cells are stem cells present within the teeth or other oral structures. They are commonly sourced from the dental pulp, the soft area within the center of the tooth. These stem cells have many uses related to tooth regeneration and repair. They also have the potential to be used across of range of regenerative medicine applications, addressing ailments from bone injuries to heart disease and arthritis. [Read more…]
What Stem Cell Clinics Do You Trust?
On a global basis, stem cell clinics have proliferated in recent years. This article explores stem cell centers within the U.S. and worldwide. Read on to learn about this emerging area of medicine. [Read more…]
Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
TAMPA, Fla. and CAMBRIDGE, Mass., March 11, 2026 – GelMEDIX Inc., a biotechnology company developing regenerative therapies to restore vision, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a global partnership to access Catalent’s GMP-induced pluripotent stem cells (iPSC) and Catalent’s cell therapy manufacturing expertise and capabilities to support the development and clinical manufacturing of GelMEDIX’s iPSC-derived cell therapies to treat ocular and retinal diseases. [Read more…]
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 202
- Next Page »